This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shibayama, T.
Right arrow Articles by Kuwahara, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shibayama, T.
Right arrow Articles by Kuwahara, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2006, p. 4186-4188, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00494-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of CS-023 (RO4908463), a Novel Parenteral Carbapenem, in Healthy Male Caucasian Volunteers{triangledown}

Takahiro Shibayama,1* Yoko Matsushita,1 Takashi Hirota,1 Toshihiko Ikeda,1 and Shogo Kuwahara2

Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan,1 Toho University School of Medicine, Ohta-ku, Tokyo, Japan2

Received 21 April 2006/ Returned for modification 10 August 2006/ Accepted 10 September 2006

The CS-023 concentration in plasma after administration by infusion to healthy volunteers at a dose of 700 mg was decreased, with a half-life of 1.7 h, and the cumulative urinary excretion was 59.4% of the dose. The total clearance, renal clearance, and volume of distribution were 8.12 liters/h, 4.14 liters/h, and 17.2 liters, respectively.


* Corresponding author. Mailing address: Drug Metabolism and Pharmacokinetics Research Laboratories, Sankyo Co., Ltd., 2-58 Hiromachi 1-chome, Shinagawa-ku, Tokyo 140-8710, Japan. Phone: 81-3-3492-3131. Fax: 81-3-5436-8567. E-mail: sibaya{at}sankyo.co.jp.

{triangledown} Published ahead of print on 16 October 2006.


Antimicrobial Agents and Chemotherapy, December 2006, p. 4186-4188, Vol. 50, No. 12
0066-4804/06/$08.00+0     doi:10.1128/AAC.00494-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Tanaka, K., Mikamo, H., Nakao, K., Ichiishi, T., Goto, T., Yamagishi, Y., Watanabe, K. (2009). In Vitro Activity of Tomopenem (CS-023/RO4908463) against Anaerobic Bacteria. Antimicrob. Agents Chemother. 53: 319-322 [Abstract] [Full Text]  
  • Morinaga, Y., Yanagihara, K., Nakamura, S., Yamamoto, K., Izumikawa, K., Seki, M., Kakeya, H., Yamamoto, Y., Yamada, Y., Kohno, S., Kamihira, S. (2008). In vivo efficacy and pharmacokinetics of tomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection model. J Antimicrob Chemother 62: 1326-1331 [Abstract] [Full Text]  
  • Koga, T., Masuda, N., Kakuta, M., Namba, E., Sugihara, C., Fukuoka, T. (2008). Potent In Vitro Activity of Tomopenem (CS-023) against Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 52: 2849-2854 [Abstract] [Full Text]  
  • Mallalieu, N. L., Lennon, S., Liu, M., Kirkpatrick, C., Robson, R., Luedin, E., Davies, B. E. (2008). Effect of Impaired Renal Function on the Pharmacokinetics of Tomopenem (RO4908463/CS-023), a Novel Carbapenem. Antimicrob. Agents Chemother. 52: 2360-2366 [Abstract] [Full Text]  
  • MacGowan, A. P., Bowker, K. E., Noel, A. R. (2008). Pharmacodynamics of the Antibacterial Effect and Emergence of Resistance to Tomopenem, Formerly RO4908463/CS-023, in an In Vitro Pharmacokinetic Model of Staphylococcus aureus Infection. Antimicrob. Agents Chemother. 52: 1401-1406 [Abstract] [Full Text]